Confidence+ in our support program

Dealing with hyperphosphatemia can be challenging for your patients with end stage renal disease (ESRD). And you can't be with them all the time. That's why we created the FOSRENOL On Track™ Support Program, a support program that reinforces your efforts and provides patients with materials that may help them manage their condition.

Indication

  • FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Important Safety Information

  • FOSRENOL is contraindicated in patients with bowel obstruction, ileus, and fecal impaction.
  • Serious cases of gastrointestinal obstruction, ileus, and fecal impaction have been associated with lanthanum use, some requiring surgery or hospitalization. Risk factors include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications.
  • Instruct patients to chew or crush the tablet completely to reduce the risk of serious adverse gastrointestinal events. Advise patients with poor dentition that they may crush tablets completely. Advise patients to take FOSRENOL with or immediately after meals.
  • Patients with acute peptic ulcer, ulcerative colitis, Crohn’s disease, or bowel obstruction were not included in FOSRENOL clinical studies.
  • FOSRENOL has radio-opaque properties and may give the appearance typical of an imaging agent during abdominal X-ray procedures.
  • The most common adverse reactions seen with FOSRENOL in clinical trials included nausea, vomiting, diarrhea, and abdominal pain.
  • There is potential for FOSRENOL to interact with:
    • compounds that bind to cationic antacids (ie, aluminum-, magnesium-, or calcium-based)
    • oral quinolone antibiotics
    • thyroid hormone replacement therapy
    These concomitant medications should be dosed separately from FOSRENOL to avoid drug interactions. See the Full Prescribing Information for dosing recommendations.
  • FOSRENOL is Pregnancy Category C. FOSRENOL is not recommended for use during pregnancy. It is not known whether FOSRENOL is excreted in human milk. Use caution when prescribing FOSRENOL to a nursing woman.
  • The safety and efficacy of FOSRENOL in pediatric patients have not been established. The use of FOSRENOL in this population is not recommended.

Please click here for Full Prescribing Information for FOSRENOL (lanthanum carbonate).

Help your patients get started with the FOSRENOL On Track™ Support Program.
Enroll Now

Help your patients get started on the FOSRENOL On Track™ Support Program.

Shire Cares: Patient Assistance & Support Program. Learn More
X

The site you are accessing is maintained by a third party over whom Shire has no control. Shire does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site.

Shire is not responsible for third-party content or the consequences of your use thereof.

Do you wish to continue?